Table 1.

Clinical trials with RNAi-based therapies (Available online: https://clinicaltrials.gov, accessed on 20 November 2020).

Name	Target	Disease	Phase	Carrier	Status	Ref.
Mesenchymal stromal cell-derived exosomes with KRAS G12D siRNA	KrasG12D	Metastatic pancreatic adenocarcinoma, Pancreatic ductal adenocarcinoma, Stage IV Pancreatic Cancer AJCCv8	Ⅰ	Exosome	Not yet recruiting	[10]
EphA2-siRNA	EphA2	Advanced malignant solid neoplasm	Ⅰ	Liposomes	Recruiting	[11]
Atu027	PKN3	Advanced solid tumors, Carcinoma, Pancreatic Ductal	Ⅰ Ⅱ	Liposomes	Completed Completed Completed Completed	[8] [12] [13] [14]
CALAA-01	RRM2	Solid tumors	Ⅰ	Cyclodextrin polymer-based NPs	Terminated	[15]
DCR-MYC	MYC	Hepatocellular Carcinoma, Solid tumors, Multiple myeloma, non-Hodgkin’s lymphoma, pancreatic neuroendocrine tumors, PNET, NHL	Ⅰ II	Lipid nanoparticle	Terminated	[16,17]
TKM-080301	PLK1	Hepatocellular Carcinoma Hepatoma Liver cancer, Adult liver cell Carcinoma, Adultneuroendocrine tumors, NET, Adrenocortical carcinoma, ACC, Colorectal cancer with hepatic metastases, Pancreas cancer with hepatic metastases, Gastric cancer with hepatic metastases, Breast cancer with hepatic metastases, Ovarian cancer with hepatic metastases	Ⅰ II	Lipid nanoparticle	Completed	[18] [19] [20]
siG12D LODER	KRAS	Pancreatic ductal adenocarcinoma, Pancreatic cancer	Ⅰ	Miniature biodegradable polymeric matrix	Completed	[21]